Literature DB >> 17701183

Delineation and segmentation of cerebral tumors by mapping blood-brain barrier disruption with dynamic contrast-enhanced CT and tracer kinetics modeling-a feasibility study.

S Bisdas1, X Yang, C C T Lim, T J Vogl, T S Koh.   

Abstract

Dynamic contrast-enhanced (DCE) imaging is a promising approach for in vivo assessment of tissue microcirculation. Twenty patients with clinical and routine computed tomography (CT) evidence of intracerebral neoplasm were examined with DCE-CT imaging. Using a distributed-parameter model for tracer kinetics modeling of DCE-CT data, voxel-level maps of cerebral blood flow (F), intravascular blood volume (vi) and intravascular mean transit time (t1) were generated. Permeability-surface area product (PS), extravascular extracellular blood volume (ve) and extraction ratio (E) maps were also calculated to reveal pathologic locations of tracer extravasation, which are indicative of disruptions in the blood-brain barrier (BBB). All maps were visually assessed for quality of tumor delineation and measurement of tumor extent by two radiologists. Kappa (kappa) coefficients and their 95% confidence intervals (CI) were calculated to determine the interobserver agreement for each DCE-CT map. There was a substantial agreement for the tumor delineation quality in the F, ve and t1 maps. The agreement for the quality of the tumor delineation was excellent for the vi, PS and E maps. Concerning the measurement of tumor extent, excellent and nearly excellent agreement was achieved only for E and PS maps, respectively. According to these results, we performed a segmentation of the cerebral tumors on the base of the E maps. The interobserver agreement for the tumor extent quantification based on manual segmentation of tumor in the E maps vs. the computer-assisted segmentation was excellent (kappa = 0.96, CI: 0.93-0.99). The interobserver agreement for the tumor extent quantification based on computer segmentation in the mean images and the E maps was substantial (kappa = 0.52, CI: 0.42-0.59). This study illustrates the diagnostic usefulness of parametric maps associated with BBB disruption on a physiology-based approach and highlights the feasibility for automatic segmentation of cerebral tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17701183     DOI: 10.1007/s00330-007-0726-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition.

Authors:  F Calamante; D G Gadian; A Connelly
Journal:  Magn Reson Med       Date:  2000-09       Impact factor: 4.668

2.  Functional CT imaging of prostate cancer.

Authors:  Elizabeth Henderson; Michael F Milosevic; Masoom A Haider; Ivan W T Yeung
Journal:  Phys Med Biol       Date:  2003-09-21       Impact factor: 3.609

3.  Dynamic contrast-enhanced computed tomography (CT) for quantitative estimation of microvascular permeability in human brain tumors.

Authors:  Heidi C Roberts; Timothy P L Roberts; Ting-Yim Lee; William P Dillon
Journal:  Acad Radiol       Date:  2002-08       Impact factor: 3.173

Review 4.  MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome.

Authors:  N A Mayr; H Hawighorst; W T Yuh; M Essig; V A Magnotta; M V Knopp
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

5.  The permeability of brain capillaries to non-electrolytes.

Authors:  C Crone
Journal:  Acta Physiol Scand       Date:  1965-08

6.  Dynamic, contrast-enhanced CT of human brain tumors: quantitative assessment of blood volume, blood flow, and microvascular permeability: report of two cases.

Authors:  Heidi C Roberts; Timothy P L Roberts; Ting-Yim Lee; William P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2002-05       Impact factor: 3.825

7.  A physiologic model of capillary-tissue exchange for dynamic contrast-enhanced imaging of tumor microcirculation.

Authors:  T S Koh; L H Cheong; Z Hou; Y C Soh
Journal:  IEEE Trans Biomed Eng       Date:  2003-02       Impact factor: 4.538

8.  Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors.

Authors:  H C Roberts; T P Roberts; A W Bollen; S Ley; R C Brasch; W P Dillon
Journal:  Acad Radiol       Date:  2001-05       Impact factor: 3.173

9.  Can in vivo assessment of tissue hemodynamics with dynamic contrast-enhanced CT be used in the diagnosis of tumors and monitoring of cancer therapy outcomes?

Authors:  Wlad T Sobol; Joel K Curé
Journal:  Radiology       Date:  2004-09       Impact factor: 11.105

10.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Authors:  M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

View more
  3 in total

1.  Dynamic perfusion CT assessment of the blood-brain barrier permeability: first pass versus delayed acquisition.

Authors:  J W Dankbaar; J Hom; T Schneider; S-C Cheng; B C Lau; I van der Schaaf; S Virmani; S Pohlman; W P Dillon; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2008-07-17       Impact factor: 3.825

2.  Dynamic in vivo imaging of cerebral blood flow and blood-brain barrier permeability.

Authors:  Ofer Prager; Yoash Chassidim; Chen Klein; Haviv Levi; Ilan Shelef; Alon Friedman
Journal:  Neuroimage       Date:  2009-08-12       Impact factor: 6.556

Review 3.  Blood-brain barrier permeability imaging using perfusion computed tomography.

Authors:  Jernej Avsenik; Sotirios Bisdas; Katarina Surlan Popovic
Journal:  Radiol Oncol       Date:  2015-03-25       Impact factor: 2.991

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.